Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2Thoracic 1NET 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 112Breast Neoplasms 87Carcinoma, Non-Small-Cell Lung 85Glioblastoma 72Ovarian Neoplasms 62Brain Neoplasms 45Lung Neoplasms 41Glioma 41Fallopian Tube Neoplasms 41Neoplasms 38Colonic Neoplasms 34Gliosarcoma 33Carcinoma, Renal Cell 32Rectal Neoplasms 31Neoplasm Metastasis 29Pancreatic Neoplasms 19Carcinoma, Hepatocellular 19Melanoma 18Adenocarcinoma of Lung 18Astrocytoma 15Kidney Neoplasms 13Stomach Neoplasms 12Prostatic Neoplasms 12Uterine Cervical Neoplasms 11Oligodendroglioma 11Liver Neoplasms 11Esophageal Neoplasms 11Sarcoma 10Adenocarcinoma, Bronchiolo-Alveolar 10Central Nervous System Neoplasms 9

Interventions

Temozolomide 3Capecitabine 3Everolimus 2Bevacizumab 2regorafenib 1motesanib diphosphate 1batifiban 1Sorafenib 1Oxaliplatin 1Octreotide 1Leucovorin 1Fluorouracil 1Fentanyl 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Gastrinoma × Bevacizumab × Clear all
NCT01525082 2024-02-06

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Stanford University

Phase 2 Completed
20 enrolled 15 charts
EndocrineGastrointestinal

Glucagonoma, Insulinoma, Pancreatic Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡